About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker EXEL · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lu…
NCT07845786 · Squamous Non-Small Cell Lung Cancer (NSCLC)
Carboplatin, Paclitaxel
EXEL
Exelixis
Phase 2Recruiting
was not yet recruiting
60Jun 15, 2028Registry ↗
Nov 12, 2026Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants…
NCT07750158 · Colorectal Cancer
Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa
EXEL
Exelixis
Phase 3Recruiting600Apr 5, 2030Registry ↗
Nov 6, 2026A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tum…
NCT05932862 · Advanced Solid Tumor
XL309, Olaparib
EXEL
Exelixis
Phase 1Active, not recruiting
was recruiting
429Apr 30, 2027Registry ↗
Oct 30, 2026Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine…
NCT06943755 · Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Ne…
Zanzalintinib, Everolimus
EXEL
Exelixis
Phase 2/3Recruiting440Jun 30, 2029Registry ↗
Oct 30, 2026Study of XB010 in Subjects With Solid Tumors
NCT06545331 · Locally Advanced or Metastatic Solid Tumors, Esophageal Squ…
XB010, Pembrolizumab
EXEL
Exelixis
Phase 1Recruiting396Nov 23, 2026Registry ↗
Oct 28, 2026Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
NCT07620574 · Cancer, Renal Cell Carcinoma (RCC)
Cabozantinib, Zanzalintinib
EXEL
Exelixis
Phase 3Enrolling by invitation5,000May 31, 2030Registry ↗
Oct 28, 2026A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616 · Meningioma
Zanzalintinib
EXEL
Exelixis
Phase 2Recruiting100Feb 29, 2028Registry ↗
Oct 20, 2026Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untr…
NCT03937219 · Renal Cell Carcinoma
Cabozantinib, Nivolumab
EXEL
Exelixis
Phase 3Active, not recruiting855Jan 31, 2022Registry ↗
Oct 20, 2026A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiate…
NCT03690388 · Differentiated Thyroid Cancer
Cabozantinib, Placebo
EXEL
Exelixis
Phase 3Active, not recruiting187Aug 19, 2020Registry ↗
Oct 20, 2026A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid…
NCT01896479 · Medullary Thyroid Cancer
Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
EXEL
Exelixis
Phase 4Active, not recruiting247Jul 15, 2020Registry ↗
Oct 1, 2026Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Sol…
NCT05176483 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant…
Zanzalintinib, Nivolumab
EXEL
Exelixis
Phase 1Recruiting1,394Jan 31, 2027Registry ↗
Oct 1, 2026Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced o…
NCT03170960 · Urothelial Carcinoma, Renal Cell Carcinoma
cabozantinib, atezolizumab
EXEL
Exelixis
Phase 1Active, not recruiting914Feb 21, 2023Registry ↗
Aug 19, 2026Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCT07773454 · Cancer, Pediatric Cancer
Zanzalintinib
EXEL
Exelixis
Phase 1Not yet recruiting18Jul 31, 2028Registry ↗
Jul 29, 2026Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Rena…
NCT05678673 · Non-Clear Cell Renal Cell Carcinoma
XL092, Nivolumab
EXEL
Exelixis
Phase 3Active, not recruiting317Dec 15, 2026Registry ↗
Jul 17, 2026Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940 · Colorectal Cancer
XL092, Atezolizumab
EXEL
Exelixis
Phase 3Active, not recruiting901Jun 16, 2026Registry ↗
Jun 24, 2026A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advance…
NCT06952010 · Solid Tumor, Advanced Solid Tumor
XB628, Zanzalintinib
EXEL
Exelixis
Phase 1Recruiting303May 31, 2027Registry ↗
Feb 25, 2026Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or…
NCT01068782 · Astrocytic Tumors
Cabozantinib
EXEL
Exelixis
Phase 2Terminated19May 2011Registry ↗
Feb 17, 2026A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103 · Solid Tumors
XB371
EXEL
Exelixis
Phase 1Recruiting150Nov 2027Registry ↗
Jan 13, 2026A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Canc…
NCT00596648 · Carcinoma, Non-Small-Cell Lung
XL184, erlotinib
EXEL
Exelixis
Phase 1/2Completed92Aug 2, 2012Registry ↗
Jan 8, 2026Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
NCT01995058 · Prostate Cancer, Castration Resistant Prostate Cancer
cabozantinib, abiraterone
EXEL
Exelixis
Phase 2Terminated54Nov 2014Registry ↗
Dec 18, 2025Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117 · Metastatic Prostate Cancer, Prostate Adenocarcinoma
Cabozantinib, Atezolizumab
EXEL
Exelixis
Phase 3Active, not recruiting575Apr 19, 2024Registry ↗
Dec 11, 2025Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanc…
NCT03755791 · Hepatocellular Carcinoma
Cabozantinib, Cabozantinib
EXEL
Exelixis
Phase 3Active, not recruiting837Nov 30, 2021Registry ↗
Aug 17, 2025Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Rec…
NCT06082167 · Head and Neck Squamous Cell Carcinoma
Zanzalintinib, Zanzalintinib-matched Placebo
EXEL
Exelixis
Phase 2/3Active, not recruiting600Aug 2028Registry ↗
Jun 25, 2025A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced…
NCT06630247 · Solid Cancers, Solid Tumor Cancer
XL495, ADC cytotoxic agents
EXEL
Exelixis
Phase 1Terminated9May 7, 2025Registry ↗
Jun 22, 2025Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment…
NCT06962332 · Hepatic Impairment, Moderate Hepatic Impairment
Zanzalintinib
EXEL
Exelixis
Phase 1Recruiting20Dec 2025Registry ↗
Jun 12, 2025Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With A…
NCT06191796 · Advanced Clear Cell Renal Cell Carcinoma or Other Advanced…
zanzalintinib, AB521
EXEL
Exelixis
Phase 1Terminated25May 12, 2025Registry ↗
Apr 4, 2025Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT04925284 · Non Small Cell Lung Cancer, Cervical Cancer
XB002, Nivolumab
EXEL
Exelixis
Phase 1Completed269Mar 10, 2025Registry ↗
Nov 19, 2024A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166 · Neoplasm Malignant, Renal Cell Carcinoma
XL092, Atezolizumab
EXEL
Exelixis
Phase 1Active, not recruiting325Aug 31, 2026Registry ↗
May 14, 2024Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
NCT04726332 · Neoplasm Malignant, Epithelial Ovarian Cancer
XL102, Fulvestrant
EXEL
Exelixis
Phase 1Terminated52May 2, 2024Registry ↗
Apr 25, 2024Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
NCT00940225 · Solid Tumors, Cancer
Cabozantinib, Placebo
EXEL
Exelixis
Phase 2Completed730May 2013Registry ↗
Feb 5, 2024Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
NCT00704288 · Glioblastoma Multiforme
XL184
EXEL
Exelixis
Phase 2Completed222Jun 2012Registry ↗
Jul 11, 2023Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
NCT05144347 · Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse…
XL114
EXEL
Exelixis
Phase 1Terminated2Nov 1, 2022Registry ↗
May 6, 2021Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Receive…
NCT01908426 · Hepatocellular Carcinoma
Cabozantinib tablets, Placebo tablets
EXEL
Exelixis
Phase 3Completed707Oct 16, 2017Registry ↗
Apr 27, 2021A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT01865747 · Renal Cell Carcinoma
Cabozantinib tablets, Everolimus (Afinitor) tablets
EXEL
Exelixis
Phase 3Completed658May 22, 2015Registry ↗
Apr 20, 2021Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
NCT00704730 · Thyroid Cancer
XL184, Placebo
EXEL
Exelixis
Phase 3Completed330Oct 2011Registry ↗
May 23, 2018Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Sy…
NCT01522443 · Prostate Cancer, Castration Resistant Prostate Cancer
cabozantinib, mitoxantrone
EXEL
Exelixis
Phase 3Terminated119Oct 2014Registry ↗
Mar 14, 2018Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostat…
NCT01605227 · Prostate Cancer, Castration Resistant Prostate Cancer
cabozantinib, prednisone
EXEL
Exelixis
Phase 3Completed1,028Sep 2014Registry ↗
Aug 21, 2015Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
NCT00796484 · Cancer
XL888
EXEL
Exelixis
Phase 1Terminated33Nov 2010Registry ↗
Aug 21, 2015A Phase 1 Study of XL019 in Adults With Polycythemia Vera
NCT00595829 · Polycythemia Vera
XL019
EXEL
Exelixis
Phase 1Terminated3Feb 2009Registry ↗
Aug 21, 2015Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
NCT00526838 · Cancer, Lymphoma
XL228
EXEL
Exelixis
Phase 1Terminated84Dec 2010Registry ↗
Aug 21, 2015A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With…
NCT00475917 · Cancer, Lymphoma
XL844, Gemcitabine
EXEL
Exelixis
Phase 1Terminated28Dec 2008Registry ↗
Aug 21, 2015Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute…
NCT00464113 · Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, P…
XL228
EXEL
Exelixis
Phase 1Terminated49Dec 2010Registry ↗
Aug 20, 2015Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
NCT01553656 · Solid Tumors, Cancer
cabozantinib capsules, cabozantinib tablets
EXEL
Exelixis
Phase 1Completed85May 2015Registry ↗
Aug 20, 2015Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
NCT00704392 · Cancer, Non-small-cell Lung Cancer
XL647, XL147
EXEL
Exelixis
Phase 1Withdrawn0Dec 2009Registry ↗

44 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:42 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances